Gliom kliniske forsøg i Minnesota
13 studier for Gliom søger deltagere på steder i Minnesota.
Byer i Minnesota
Officiel studietekst (engelsk)
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
- Mayo Clinic in Rochester, Rochester
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07025226A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
RekruttererFase 1/2
12 Months – 21 Years · Alle køn · Opdateret 1. okt. 2026 · NCT05099003SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Mayo Clinic - Rochester, Rochester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Children's Minnesota, Minneapolis
RekruttererFase 1
Alder 1 til 25 · Alle køn · Opdateret 18. aug. 2026 · NCT04485559Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions
- Mayo Clinic in Rochester, Rochester
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT04047264A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
- Mayo Clinic in Rochester, Rochester
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT07074756A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- St. Luke's Hospital, Duluth
RekruttererFase 2
Alder 8 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT05503797Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
- Mayo Clinic in Rochester, Rochester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. jun. 2026 · NCT07468136Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 19 og opefter · Alle køn · Opdateret 8. jun. 2026 · NCT06011109Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Mayo Clinic Cancer Center, Rochester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06810544Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
- Mayo Clinic in Rochester, Rochester
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 24. mar. 2026 · NCT06482905Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
- Mayo Clinic in Rochester, Rochester
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 4. nov. 2025 · NCT05717153CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
- Children's Minnesota, Minneapolis
RekruttererFase 1
Alder 2 til 25 · Alle køn · Opdateret 12. mar. 2024 · NCT06305910Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.